Physician profile
Sara Lamb
NPI 1376907402
$2,854.50
in general payments reported to CMS, 2019-2025
21 companies · $1,647 in 2025
The $1,647 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $234 · 2020: $17.50 · 2021: $88.84 · 2022: $558 · 2024: $309 · 2025: $1,647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,956.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,956.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $506.87 | 2019-2025 | Dupixent |
| Abbvie INC. | $373.49 | 2019-2025 | |
| Janssen Biotech, INC. | $353.56 | 2021-2025 | Tremfya |
| Arcutis Biotherapeutics, INC. | $243.42 | 2025 | Zoryve |
| Lilly USA, LLC | $224.93 | 2022-2025 | Taltz, Ebglyss |
| Genzyme Corporation | $215.09 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $179.78 | 2022-2025 | |
| Amgen INC. | $173.02 | 2022-2025 | Otezla |
| Incyte Corporation | $123.10 | 2021-2025 | Opzelura |
| Revance Therapeutics, INC. | $102.96 | 2025 | Daxxify |
| Pfizer INC. | $66.94 | 2020-2022 | |
| Leo Pharma INC. | $51.64 | 2022 | |
| Ucb, INC. | $49.43 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $32.83 | 2024-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Organon LLC | $32.38 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $30.52 | 2024-2025 | |
| Kerecis Limited | $25.25 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Helsinn Therapeutics (U.S.), INC. | $22.45 | 2024 | Valchlor |
| Galderma Laboratories, L.P. | $17.93 | 2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.45 | 2024 | Spevigo |
| Biowound Solutions, INC. | $13.46 | 2025 | Bio-Connekt |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sara Lamb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.